pfizer lot numbers lookup

COVID-19 Pfizer BioNTech Vaccine EUA Recipient-Caregiver Fact Sheet; 4/6/2021 253088698300033211201201; 0886983000332 Historic; 5/10/2021 COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet-12 years and older; 12/8/2022 253088698300033211210501; 0886983000332 Historic; 4/18/2023 COVID-19 Novavax EUA Recipient-Caregiver Fact Sheet Clinical trials showed that beginning 1 week after the second dose, the Pfizer-BioNTech Comirnaty COVID vaccine was about: Effectiveness data supporting the authorization in children ages 6 months to under 5 years are based on a comparison of immune responses in this age group to individuals ages 16 to 25 years. In this Report, registered users can access COVID-19 vaccine lot numbers, expiration dates, and National Drug Codes (NDCs) provided by the vaccine manufacturers to CDC from downloadable tabular files for use in vaccine administration, inventory . . reference number. All Pfizer-BioNTech COVID-19 vaccine formulations are administered intramuscularly and can be stored in either a refrigerator or ultra-cold freezer. Note: The VIS Fully-Encoded Text String is used for electronic reporting purposes. Ensure the ID on the card matches a driver's license, then check for appropriate dose intervals. The monovalent Pfizer COVID-19 vaccine for children 6 months through 4 years of age will continue to be used for the first and second doses of the three-dose primary series. Children aged 4 who will turn 5 years of age between their doses in the vaccination series should receive their age-appropriate dose at the time of the vaccination. All Pfizer COVID-19 vaccine shipments will continue to have supporting Controlant DDL in-transit temperature monitoring. The CDC itself doesn't propose any specific criteria to assess the authenticity of vaccination cards. * note: only Moderna, Pfizer-BioNTech/Comirnaty and Johnson & Johnson (Janssen) vaccines are currently authorized for administration in the United . Pfizer-BioNTech COVID-19 Vaccine, Bivalent has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals aged 6 months of age and older. A different vaccine may be offered for your second dose, if appropriate. All rights reserved. The UoS is the Unit of Shipment and is the lot number for the vaccine packaging. CDCs COVID-19 Vaccine Expiration Date Tracking Tool can help providers keep track of the expiration date by lot number. Vaccine safety has been and will continue to be one of CDCs top priorities. The syringes in the ancillary kit with the one-inch needle (attached or separate) are LDV syringes and the 1.5-inch needle/syringe combination (attached or separate) are not considered LDV syringes. %PDF-1.7 The lot number you entered (AB0000) does not exist. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week's new allocation of 2nd doses. This product information is intended only for residents of the United States. Use Pfizer-BioNTech's expiration date tool at lotexpiry.cvdvaccine.com to determine the vaccine's expiration date. Questions regarding this table should be directed to the IIS Technical Assistance Team (or use IIS mailing address). If you need to go back and make any changes, you can always do so by going to our Privacy Policy page. Manufacturers can now begin electronic submission of post marketing lot distribution data for all regulated vaccine and other biological products marketed with biologic license applications (BLAs). This also makes it easier to administer smaller doses to younger children. COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet- Pediatric 5yrs to <12 yrs: 12/08/2022: 253088698300042411211001: 0886983000424 . Once vials are thawed, they should not be refrozen. The site is secure. Name: Pfizer-BioNTech Comirnaty COVID-19 vaccine, Manufacturer: BioNTech Manufacturing GmbH, Approved for: Primary series in individuals age 6 months and older or as a booster dose in individuals age 5 to 11 years as well as 16 years and older (Pfizer-BioNTech Comirnaty COVID-19 vaccine), As a bivalent booster dose (Pfizer-BioNTech Comirnaty Original and Omicron BA.4/BA.5 in individuals age 5 years and older, As a bivalent booster dose (Pfizer-BioNTech Comirnaty Original and Omicron BA.1 in individuals age 12 years and older, How it's given: Injection in muscle (usually the upper arm). Expiration Date . Data Systems Tracking COVID-19 Vaccine Distribution and Administration, Breakthrough Case Investigations and Reporting, Centers for Disease Control and Prevention. Featured . Pfizer, Inc : Pfizer-BioNTech COVID-19 Vaccine/Comirnaty . The vaccine vials with orange caps and an orange border on the label are used to prepare the dose for individuals 5 to 11 years of age. is intended to assist manufacturers of vaccines and other biological products to electronically submit post marketing lot distribution data to FDA under 21 . On June 10, 2014, FDA issued a rule which, among other things, amended 21 CFR 600.81 to require applicants to submit Lot distribution reports to FDA in an electronic format that the Agency can process, review and archive. CDC Guidance for Planning Vaccination Clinics Held at Satellite, Temporary, or Off-Site Locations, COVID-19 Vaccination Site Accessibility Checklist (English), COVID-19 Vaccination Site Accessibility Checklist (Spanish), All CDC Guidance on Vaccine Administration, Summary List of User Guides and Previously Recorded Training Sessions, Latest Vaccine Guidance and Information for Providers, How to View Vaccination Information - Provider. Long-term storage: Ultra Cold -90C to -60C (-130F to -76F)* Do NOT store at -25C to -15C (-13F to 5F). A lock (LockA locked padlock) or https:// means youve safely connected to the .gov website. Pfizer and BioNTech have the following COVID-19 vaccine formulations for: The Wisconsin Department of Health Services (DHS) supports the CDC's (Centers for Disease Control and Prevention) recommendation that children 6 months through 4 years of age are now eligible to receive the bivalent Pfizer COVID-19 vaccine as the third dose as part of their primary series. The vaccine must be transferred into proper storage immediately and the DDLs should be deactivated once the shipping container is empty. If your last COVID vaccine was before September 2022, youre due for an updated dose. Most manufacturers have submitted biological product lot distribution reports required under 21 CFR 600.81 in the form of printed paper reports, sometimes accompanied by electronic data files as American Standard Code for Information Interchange (ASCII) flat files, XML files or in other formats. Additional information on Pfizer storage and handling may be found on CDC's webpage, Administration Overview for Pfizer-BioNTech COVID-19 Vaccine. Take this opportunity to read through the instructions linked above. Organization Type Other (Describe) The new files include COVID-19 vaccine National Drug Codes (NDCs), lot numbers, and lot expiration dates. Contact your health care provider if you experience: Health care providers must report possible reactions following vaccination to their local public health authority. This applies to COVID-19 vaccines that have received full FDA approval and emergency use authorization. It is important to select the code that has been created for that manufacturers vaccine. 176 0 obj <>stream The National Advisory Committee on Immunization (NACI) recommends an mRNA vaccine (Pfizer-BioNTech Comirnaty or Moderna Spikevax) should be offered for your second dose. This technology is designed primarily to help immunization providers record information about the VIS as is required by the National Childhood Vaccine Injury Act (NCVIA). It is very important to ensure that the expiration dates listed in the Wisconsin Immunization Registry (WIR) are correct. Such vaccines have a dynamic expiration date, which can change over time as additional stability data become available. Search Search . 153 0 obj <>/Filter/FlateDecode/ID[]/Index[125 52]/Info 124 0 R/Length 126/Prev 163118/Root 126 0 R/Size 177/Type/XRef/W[1 3 1]>>stream One group identifies a specific vaccine product and the other provides a vaccine administration code that is both vaccine and dose specific. The 2D barcoded VIS allows providers to scan the name and edition date of a VIS into an electronic medical record (EMR), IIS, or other electronic database. Select the links below to learn more about the enrollment process, and the advantages of each reporting system. Resend email confirmation. Thank you for taking the time to confirm your preferences. Business owners can also consider outsourcing the process of evaluating vaccine and booster documentation using a vaccine passport app. For enquiries,contact us. The thermal container maintains a temperature range of -90C to -60C (-130F to -76F). x\[o8~G{0UPHtvyPl6XYI6CIm=t:[W~N.e1#nx]b?6l8=I)K'di1mSM<=xLTkx4cFrhzl/OO'%`i oHe@9'_z'Gh? One dose (0.2 mL) contains 10 micrograms of COVID-19 mRNA vaccine. For example, you may have received Pfizer-BioNTech Comirnaty as your first dose and be offered Moderna Spikevax as your second. . It does not start in September. The dosing for 6 months to less than 5 years is a 3-dose primary series of 3 micrograms each of the vaccine. Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data. To stay informed about the latest news from the CDC, guides, clinical information, and more visit the COVID-19 vaccine development section. 5% of the batches appear to have produced 90% of the adverse reactions Some Pfizer batches are associated with 30 x the number of deaths and disabilities compared to other batches Again, this is called "advocate approach". There are two fields contained within the 2D barcode on the VIS. These decisions are based on public health recommendations and the latest evidence. Pfizer COVID-19 vaccine: This vaccine product has an expiration date located on the vaccine vial. Pfizer-BioNTech COVID-19 Vaccine Expiration Date Extension and Beyond-Use Date Recently the Food and Drug Administration (FDA) extended the expiration date for Pfizer-BioNTech COVID-19 Vaccine (monovalent and bivalent) from 12 to 18 . The VIS Lookup table contains codes for these fields that EMRs and IISs may need to add to their applications to accommodate this information and associates each code with its human readable equivalent. Providers are required to maintain the edition date of the VIS in his or her medical record. Moderna COVID-19 Vaccine Packaging . I verify that Im in the U.S. and agree to receive communication from the AMA or third parties on behalf of AMA. The bivalent Pfizer vaccine should be administered as the third dose in the primary series at least 2 months after second monovalent Pfizer dose. When in doubt about the appearance of a nonstandard card, contact the vaccination site (or system issuing the card) directly to verify. Do not use the vaccine in this shipment until you have received the quality report from Controlant advising on further use. Saving Lives, Protecting People, COVID-19 Vaccine Breakthrough Case Investigation and Reporting, Clinical Decision Support for Immunization (CDSi), COVID-19 Vaccine Lot Number and Expiration Date Tool, National Center for Immunization and Respiratory Diseases, Use of COVID-19 Vaccines in the U.S.: Appendices, FAQs for the Interim Clinical Considerations, Myocarditis and Pericarditis Considerations, Jurisdictions: Vaccinating Older Adults and People with Disabilities, Vaccination Sites: Vaccinating Older Adults and People with Disabilities, Vaccinating Patients upon Discharge from Hospitals, Emergency Departments & Urgent Care Facilities, Vaccines for Children Program vs. CDC COVID-19 Vaccination Program, FAQs for Private & Public Healthcare Providers, Talking with Patients about COVID-19 Vaccination, Talking to Patients with Intellectual and Developmental Disabilities, How to Tailor COVID-19 Information to Your Audience, How to Address COVID-19 Vaccine Misinformation, Ways to Help Increase COVID-19 Vaccinations, COVID-19 Vaccination Program Operational Guidance, What to Consider When Planning to Operate a COVID-19 Vaccine Clinic, Using the COVID-Vac Tool to Assess COVID-19 Vaccine Clinic Staffing & Operations Needs, Connecting with Federal Pharmacy Partners, Resources to Promote the COVID-19 Vaccine for Children & Teens, COVID-19 Vaccine Access in Long-term Care Settings, Information for Long-term Care Administrators & Managers, Vaccinating Dialysis Patients and Healthcare Personnel, What Public Health Jurisdictions and Dialysis Partners Need to Know, Supporting Jurisdictions in Enrolling Healthcare Providers, Vaccine Administration Management System (VAMS), Resources for Jurisdictions, Clinics, and Organizations, 12 COVID-19 Vaccination Strategies for Your Community, How to Engage the Arts to Build COVID-19 Vaccine Confidence, Strategies for Reaching People with Limited Access to COVID-19 Vaccines, U.S. Department of Health & Human Services. Pfizer Safety Reporting Site *If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site. Email CDC-INFO. c. Some vaccine manufacturers will have only one lot number. Reported allergic reactions and side effects to COVID-19 vaccines are published weekly in our Reported side effects following COVID-19 vaccination report. The COVID-19 vaccines that are currently available were contractually purchased by the U.S. Government after the FDA granted authorizations for emergency use in 2020. If the test file is compliant with technical requirements, then the LDD system will return an email test acknowledgment receipt with notification for data acceptance. Vials with an orange cap and orange Original and Omicron label border contain 10 doses of 0.2 mL after dilution. The vaccine also continues to be available under emergency use authorization (EUA) for individuals 6 months to 11years of age and for the administration of a third dose in certain individuals who are immunocompromised. Only authorized for the first two doses of the three-dose primary series: two doses (0.2 mL), at least three to eight weeks apart. visit the COVID-19 vaccine development section. The report is available only . The vaccine vials with maroon caps and maroon border on the label are used to prepare the dose for individuals 6 months to less than 5 years of age. 00069-2025-1 . One dose (0.2 mL) contains 3 micrograms of COVID-19 mRNA vaccine. Step 3 Information, guidance and tools for vaccinating North Carolinians. This resource is designed to help you determine the appropriate CPT code combination for the type and dose of vaccine that you are using. The Pfizer-BioNTech COVID-19 vaccine was authorized for use in Canada under the Interim Order respecting the importation, sale and advertising of drugs for use in relation to COVID-19. Centers for Disease Control and Prevention. Authorized as a primary series: two doses (0.2 mL), three to eight weeks apart. It would violate the provider agreement and could expose providers to the following risks: Onsite temperature monitoring for Pfizer vaccines (after product acceptance) ended on November 28, 2022. They help us to know which pages are the most and least popular and see how visitors move around the site. Such vaccines have a dynamic expiration date, which can change over time as additional stability data become available. To find the expiration date, enter the lot number found on the vial or the carton into the Pfizer-BioNTech COVID-19 Vaccine Expiry Tool. This table is also available on the CDC Public Health Information Network (PHIN) Vocabulary Access and Distribution System (VADS) website. At ImmunaBand, we always check the following: Not all sites use the standard CDC card. The VIS Lookup table contains codes for these fields that EMRs and IISs may need to add to their applications to accommodate this information and associates each code with its human readable equivalent. These steps allow Points of Use (POUs) to ensure proper data connection through a manual data upload using your local internet network. Vaccinators are encouraged to use SDVs at sites where they can increase access and availability of the bivalent booster vaccine. A full set of instructions and troubleshooting information can be found on the Controlant website on receiving your single-use Controlant shipment. This is the same process that is used to order all COVID-19 vaccines. The decision to grant full approval is the result of rigorous review of thousands of pages of additional safety and efficacy data, as well as inspections of vaccine production sites, consistent with all other full approval processes. Raleigh, NC 27699-2000. Stay up to date with what you want to know. The currently available vaccine products with purple caps and a purple label border or grey caps with a grey label border are used to prepare the dose for individuals 12 years of age and older. Vial labels and cartons may state that after dilution a vial contains five doses of 0.3 mL. Manually upload the temperature monitoring data onto the computer. Beginning the following Thursday, states can begin ordering doses from that week's new allocation of 1st doses. 1 dose for the booster and bivalent booster. To access dates and links for upcoming training sessions, please visit:https://www.pfizermedicalinformation.com/en-us/medical-updates. This reporting requirement is effective as of June 10, 2015. Mix and match use of the bivalent Pfizer and Moderna COVID-19 vaccines is not currently authorized for children ages 6 months through 4 years. The first field is a code that identifies the VIS document type (MMR, seasonal influenza, anthrax, etc.). Our decisions are based only on scientific and medical evidence showing that vaccines are safe and effective. EMR and IIS vendors may need to add fields to the EMR to record the VIS document type and edition date. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL . As data become available, this list can continue to expand. If the sixth dose is not obtained, you will need to report this dose as wasted in WIR. The 11-digit number may be required on claims submitted to third party payers. Administration fees may not be reimbursable by payers. Email / Username. Product . Review FDAs Draft Guidance for Industry: Electronic Submission of Lot Distribution Reports. More information. Pfizer-BioNTech, adult and adolescent formula (purple cap): . Pfizer) COVID- mRNA, LNP-S, PF 30 EL 1283 04/30/2021 mcg/0_3 dose Pfizer) COVID- mRNA, . M&D will begin redistributing Pfizer vaccine with . The exact appearance varies with the individual site within states. Page 9 of the Controlant Onsite Temperature Monitoring Playbook for Sites provides step-by-step instructions for performing this task. To find the expiration date, enter the lot number found on the vial or the carton into the Pfizer-BioNTech COVID-19 Vaccine Expiry Tool. You can review and change the way we collect information below. On Dec. 11, the US Food and Drug Administration issued its first emergency use authorization for a Covid-19 vaccine, shortly after the UK . Clinical trials showed that beginning 1 week after the second dose, the Pfizer-BioNTech Comirnaty COVID vaccine was about: 95% effective in protecting trial participants from COVID-19 for those 16 years and older. The VIS barcode does not contain any data that is not currently on the VIS, and there is no requirement that immunizers supply VIS data to IIS. The Centers for Disease Control and Prevention (CDC) together with federal agencies, vaccine providers, jurisdictions, and state/local public health departments and tribal health facilities across the United States use these data systems to inform decision-making regarding COVID-19 vaccination. Comparisons of the different Pfizer COVID-19 vaccine formulations. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. For COVID-19 questions call800-232-4636 (TTY 888-232-6348) No Pfizer vaccine is authorized as a booster dose for this age group. Per the Pfizer emergency use authorization fact sheet for people ages 12 years and older, one vial contains six doses of 0.3 mL after dilution. Lot Numbers Aggregate Vaccine Counts Search/Add Search Results Detail Correct Decrementing . Chantix (varenicline) Tablets, 0.5 mg: 0069-0468-56: 00019213: 2022 JAN: Bottles FDA staff members then manually compiled the data into the Lot Distribution Database (LDD) system for use in post marketing safety surveillance. If vaccinators want less than 50 doses, they are instructed to list the extra doses they receive on the Wisconsin COVID-19 Vaccine Exchange. 2001 Mail Service Center The National Drug Code (NDC) uniquely identifies human drugs in the United States; it can be found on the vial containing the vaccine. Dose volume depends on which series of the vaccine is administered. The FDA authorized a second bivalent booster for certain individuals most vulnerable to severe outcomes from Covid-19. The ancillary kits are supplied to support this guidance. All rights reserved. a. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. Additional information on Pfizer storage and handling may be found at Administration Overview for Pfizer-BioNTech COVID-19 Vaccine. You can check vaccine lot numbers through the Centers for Disease Control and Prevention's COVID-19 vaccine lot number and expiration date file. They help us to know which pages are the most and least popular and see how visitors move around the site. NC Department of Health and Human Services While the elements present (other than the CDC seal) are the same as the standard CDC card, the format is different for each nonstandard card. In accordance with current automation initiatives, the FDA is moving toward electronic submission of all regulatory data in computer-readable formats in compliance with Health Level Seven (HL7) Structured Product Labeling (SPL) requirements http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. 0 Home; Register; Login; Log in. Vials with a purple cap and purple label border contain 6 doses of 0.3 mL after dilution. On this date, Pfizer-BioNTech Comirnatytransitioned to an authorization under theFood and Drug Regulations. Its safety and effectiveness in younger people has not yet been established. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use0004A, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5 mL dosage; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, single dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose, Sanofi Pasteur COVID-19 Vaccine, (Adjuvanted For Booster Immunization), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose.

Is Ray Rice Still Married To Janay Palmer, Oceanside Middle School Staff Directory, Keen Shoes Sole Falling Off, Articles P